
Article 1 

1. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2007 shall be 316 257,0 ODP kilograms.
2. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2007 shall be 65 900,9 ODP kilograms.
3. The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2007 shall be 718,7 ODP kilograms.
4. The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2007 shall be 147 110 436 ODP kilograms.
5. The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2007 shall be 672,0 ODP kilograms.
6. The quantity of controlled substances of Group VI (methyl bromide) subject to Regulation (EC) No 2037/2000 that may be used for laboratory and analytical uses in the Community in 2007 shall be 150,0 ODP kilograms.
7. The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2007 shall be 3,52 ODP kilograms.
8. The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2007 shall be 12 048 ODP kilograms.
Article 2 
The chlorofluorocarbon metered-dose inhalers listed in Annex I shall not be placed on markets where the Competent Authority has determined chlorofluorocarbons for metered-dose inhalers on those markets to be non-essential.
Article 3 
During the period 1 January to 31 December 2007 the following rules shall apply:

1.. The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.
2.. The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.
3.. The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.
4.. The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.
5.. The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.
6.. The allocation of laboratory and analytical critical use quotas for methyl bromide shall be to the companies indicated in Annex VII.
7.. The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VIII.
8.. The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex IX.
9.. The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex X.
Article 4 
This Decision shall apply from 1 January 2007 and shall expire on 31 December 2007.
Article 5 
This Decision is addressed to the following undertakings:

 3M Health Care Ltd3M House Morley StreetLoughboroughLeicestershire LE11 1EPUnited Kingdom
 Bespak Europe LtdNorth Lynn Industrial EstateBergen Way, King's LynnNorfolk PE30 2JJUnited Kingdom
 Boehringer Ingelheim GmbHBinger Straße 173D-55216 Ingelheim am Rhein
 Chiesi Farmaceutici SpAVia Palermo 26/AI-43100 Parma (PR)
 Inyx Pharmaceuticals LtdAstmoor Industrial Estate9 Arkwright Road RuncornCheshire WA7 1NUUnited Kingdom
 IVAX LtdUnit 301,Waterford Industrial EstateWeterford, Ireland
 Laboratorio Aldo Union S.A.Baronesa de Maldá 73Esplugues de LlobregatE-08950 Barcelona
 SICOR SpAVia Terrazzano 77I-20017 Rho (MI)
 Valeas SpA PharmaceuticalsVia Vallisneri, 10I-20133 Milano (MI)
 Valvole Aerosol Research Italiana (VARI) SpA — LINDAL Group ItaliaVia del Pino, 10I-23854 Olginate (LC)

 Acros Organics bvbaJanssen Pharmaceuticalaan 3aB-2440 Geel
 Airbus France316, route de BayonneF-31300 Toulouse
 Bie & Berntsen A-STransformervej 8DK-2730 Herlev
 Carlo Erba Reactifs-SDSZ.I. de Valdonne, BP 4F-13124 Peypin
 Eras Labo222, RN 90F-38330 Saint-Nazaire-les-Eymes
 Harp InternationalGellihirion Industrial Estate,Rhondda, Cynon Taff,UK-Pontypridd CF37 5SX
 Health Protection Inspectorate-LaboratoriesPaldiski mnt 81EE-10617 Tallinn
 Honeywell Specialty ChemicalsWunstorfer Straße 40Postfach 10 02 62D-30918 Seelze
 Institut scientifique de service public (ISSeP)Rue du Chéra, 200B-4000 Liège
 Ineos Fluor LtdPO Box 13, The HeathRuncorn, Cheshire WA7 4QFUnited Kingdom
 LGC Promochem GmbHMercatorstr. 51D-46485 Wesel
 Mallinckrodt Baker BVTeugseweg 207418 AM DeventerNederland
 Mebrom NVAssenedestraat 4B-9940 Rieme Ertvelde
 Merck KgaAFrankfurter Straße 250D-64271 Darmstadt
 Mikro+Polo d.o.o.Zagrebška 22SI-2000 Maribor
 Ministry of DefenseDirectorate Material RNL NavyP.O. Box 20702500 ES The HagueNederland
 Panreac Química S.A.Pol. Ind. Pla de la BrugueraC/ Garraf 2E-08211 Castellar del Vallès, Barcelona
 Sanolabor d.d.Leskoškova 4SI-1000 Ljubljana
 Sigma Aldrich Chimie SARL80, rue de LuzaisL’Isle d’Abeau-ChesnesF-38297 Saint-Quentin-Fallavier
 Sigma Aldrich LaborchemikalienWunstorfer Straße 40Postfach 10 02 62D-30918 Seelze
 Sigma Aldrich Logistik GmbHRiedstraße 2D-89555 Steinheim
 Tazzetti Fluids SrlCorso Europa, 600/aI-10088 Volpiano (TO)
 VWR I.S.A.S.201, rue CarnotF-94126 Fontenay-sous-Bois
Done at Brussels, 27 March 2007.
For the Commission
Stavros DIMAS
Member of the Commission
ANNEX I

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:


Table 1
Short acting beta agonist bronchodilators
Country Salbutamol Terbutaline Fenoterol Orciprenaline Reproterol Carbuterol Hexoprenaline Pirbuterol Clenbuterol Bitolterol Procaterol
Austria X X X X X X X X X X X
Belgium X X X X X X X X X X X
Cyprus X X X X X X X X X X X
Czech Republic X X X X X X X X X X X
Denmark X          
Estonia X X X X X X X X X X X
Finland X X X X X X X X X X X
France X X X X X X X X X X X
Germany X X X X X X X X X X X
Greece X X X X X X X X X X X
Hungary X X X X X X X X X X X
Ireland X X X X X X X X X X X
Italy X X X X X X X X X X X
Latvia X X X X X X X X X X X
Lithuania X X X X X X X X X X X
Luxembourg X X X X X X X X X X X
Malta X X X X X X X X X X X
Netherlands X X X X X X X X X X X
Poland X          
Portugal X X X X X X X X X X X
Norway X X X X X X X X X X X
Slovakia X X X X X X X X X X X
Slovenia X X X X X X X X X X X
Spain X X X X X X X X X X X
Sweden X X X X X X X X X X X
United Kingdom X          
Table 2
Inhaled steroids
Country Beclomethasone Dexamethasone Flunisolide Fluticasone Budesonide Triamcinolone
Austria X X X X X X
Belgium X X X X X X
Cyprus      
Czech Republic X X X X X X
Denmark X   X  
Estonia X X X X X X
Finland X   X  
France X   X  
Germany X X X X X X
Greece      
Hungary X X X X X X
Ireland X   X  
Italy X X X X X X
Latvia X X X X X X
Lithuania X X X X X X
Luxembourg X X X X X X
Malta    X X 
Poland      
Portugal X   X X 
The Netherlands X X X X X X
Norway      
Slovakia X X X X X X
Slovenia X X X X X X
Spain X   X  
Sweden X   X  
United Kingdom    X  
Table 3
Non steroidal anti inflammatories
Country Cromoglicic acid Nedrocromil    
Austria X X    
Belgium X X    
Cyprus X X    
Czech Republic X X    
Denmark X X    
Estonia X X    
Finland X X    
France X X    
Germany X X    
Greece X X    
Hungary X     
Ireland      
Italy X X    
Latvia X X    
Lithuania X X    
Luxembourg X     
Malta X X    
Poland      
Portugal X     
The Netherlands X X    
Norway      
Slovakia X X    
Slovenia X X    
Spain  X    
Sweden X X    
United Kingdom      
Table 4
Anticholinergic bronchodilators
Country Ipratropium bromide Oxitropium Bromide    
Austria X X    
Belgium X X    
Cyprus X X    
Czech Republic X X    
Denmark X X    
Estonia X X    
Finland X X    
France      
Germany X X    
Greece X X    
Hungary X X    
Ireland X X    
Italy      
Latvia X X    
Lithuania X X    
Luxembourg X X    
Malta X X    
Netherlands X X    
Poland      
Portugal X     
Norway      
Slovakia X X    
Slovenia X X    
Spain X X    
Sweden X X    
United Kingdom X X    
Table 5
Long acting beta agonist bronchodilators
Country Formoterol Salmeterol    
Austria X X    
Belgium X X    
Cyprus X     
Czech Republic X X    
Denmark      
Estonia X X    
Finland X X    
France X X    
Germany X X    
Greece      
Hungary X X    
Ireland X X    
Italy X X    
Latvia X X    
Lithuania X X    
Luxembourg X X    
Malta X X    
Netherlands X     
Poland      
Portugal      
Norway      
Slovakia X X    
Slovenia X X    
Spain  X    
Sweden X X    
United Kingdom      
Table 6
Combinations of active ingredients in a single MDI
Country      
Austria X All products     
Belgium X All products     
Cyprus      
Czech Republic X All products     
Denmark      
Estonia      
Finland X All products     
France X All products     
Germany X All products     
Greece      
Hungary X All products     
Ireland      
Italy Budesonide + Fenoterol Fluticasone + Salmeterol    
Latvia X All products     
Lithuania X All products     
Luxembourg X All products     
Malta X All products     
Netherlands      
Poland      
Portugal      
Norway      
Slovakia X All products     
Slovenia X All products     
Spain      
Sweden X All products     
United Kingdom      Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
ANNEX II

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:

 3 M Health Care Ltd (UK)
 Bespak Europe Ltd (UK)
 Boehringer Ingelheim GmbH (DE)
 Chiesi Farmaceutici SpA (IT)
 Inyx Pharmaceuticals Ltd (UK)
 Ivax Ltd (IE)
 Laboratorio Aldo Union SA (ES)
 SICOR SpA (IT)
 Valeas SpA Pharmaceuticals (IT)
 Valvole Aerosol Research Italiana (VARI)
SpA — LINDAL Group Italia (IT)

ANNEX III

Quota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:

 Acros Organics bvba (BE)
 Bie & Berntsen A-S (DK)
 Carlo Erba Reactifs-SDS (FR)
 Harp International (UK)
 Honeywell Specialty Chemicals (DE)
 Ineos Fluor (UK)
 LGC Promochem (DE)
 Mallinckrodt Baker (NL)
 Merck KGaA (DE)
 Mikro+Polo d.o.o. (SI)
 Panreac Química S.A. (ES)
 Sanolabor d.d. (SI)
 Sigma Aldrich Chimie (FR)
 Sigma Aldrich Logistik (DE)
 Tazzetti Fluids (IT)
 VWR I.S.A.S. (FR)

ANNEX IV

Quota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:

 Airbus France (FR)
 Eras Labo (FR)
 Ineos Fluor (UK)
 Ministry of Defense (NL)
 Sigma Aldrich Chimie (FR)

ANNEX V

Quota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:

 Acros Organics (BE)
 Bie & Berntsen A-S (DK)
 Carlo Erba Reactifs-SDS (FR)
 Health Protection Inspectorate-Laboratories (EE)
 Honeywell Specialty Chemicals (DE)
 Institut scientifique de service public (ISSeP) (BE)
 Mallinckrodt Baker (NL)
 Merck KGaA (DE)
 Mikro+Polo d.o.o. (SI)
 Panreac Química S.A. (ES)
 Sanolabor d.d. (SI)
 Sigma Aldrich Chimie (FR)
 Sigma Aldrich Laborchemikalien (DE)
 Sigma Aldrich Logistik (DE)

ANNEX VI

Quota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:

 Acros Organics (BE)
 Bie & Berntsen A-S (DK)
 Merck KGaA (DE)
 Mikro+Polo d.o.o. (SI)
 Panreac Química S.A. (ES)
 Sanolabor d.d. (SI)
 Sigma Aldrich Chimie (FR)
 Sigma Aldrich Logistik (DE)

ANNEX VII

Quota of controlled substances of Group VI that may be used for laboratory and analytical critical uses are allocated to:

 Mebrom NV (BE)
 Sigma Aldrich Logistik (DE)

ANNEX VIII

Quota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:

 Ineos Fluor (UK)
 Sigma Aldrich Chimie (FR)

ANNEX IX

Quota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:

 Ineos Fluor (UK)
 Sigma Aldrich Logistik (DE)

ANNEX X

This Annex is not published because it contains confidential commercial information.
